Photo: Govesp
Brazilian regulators have given their approval for the start of human clinical trials on ButanVac, a coronavirus vaccine developed by São Paulo’s Butantan Biological Institute.
The São Paulo government says production will be entirely domestic, though the immunizer uses technology developed by the Icahn School of Medicine at the New York-based Mount Sinai Health System.
Butantan has been waiting for approval since April and claims to have already produced 7 million doses of the vaccine, despite being a long way away from obtaining emergency use clearance. According to Butantan head Dimas Covas, the Health Ministry showed an interest in purchasing 30 million doses of ButanVac.
The specialization trend among corporate board members It is not only a matter of perception:…
Panama will hold its presidential elections on Sunday, months after huge protests saw thousands descend…
The city of Rio de Janeiro estimates that a Madonna concert this Saturday on Copacabana…
Latin America’s trend of banning opposition candidates from elections has caught on in an ever-growing…
The São Paulo City Council on Thursday approved legislation authorizing Brazil’s largest city to sign…
The preliminary report on AI regulations presented to Brazil’s Senate last week provides a middle-of-the-road…